Life Sciences M&A Report 2023

2023 showed slow signs of recovery for global life science M&A activity compared to the previous year, both in terms of the number and value of deals. While the macroeconomic challenges and uncertainty in the geopolitical landscape that fueled the 2022 slowdown carried over into 2023, there are indications that dealmakers were approaching 2023 with more optimism.

In particular, M&A activity picked up at a faster pace toward the end of the year, significantly outpacing the previous three quarters. Factors such as the patent cliff, with many important therapeutic products losing patent protection, and the dominant dealmaking activity of big pharma corporations such as Pfizer and Amgen fueled the M&A surge.

For detailed information and statistics on the latest M&A activity in the biotechnology and digital health sectors, read our Life Sciences M&A Report. Published quarterly by Venture Valuation, the report is based on comprehensive data sourced from Biotechgate.